Los Angeles, California – The Food and Drug Administration (FDA) announced a recall of all Diamond Shruumz-brand products due to concerns over potential health risks associated with the sweets. The products were found to contain high levels of compounds that violate the Federal Hazardous Substances Act.
Prophet Premium Blends, a distributor of Diamond Shruumz products, initiated the recall after reports of illnesses linked to their “microdosing” sweets. The FDA is currently investigating the presence of muscimol, a chemical found in certain mushrooms, in the products, which may explain the reported symptoms.
In addition to muscimol, chemical tests revealed the presence of O-acetylpsilocin, a psychoactive drug, in two Diamond Shruumz products. This discovery has raised concerns about the safety of consuming these chocolate bars, which also contained desmethoxyyangonin, dihydrokavain, and kavain.
The ongoing investigation has identified 39 cases of illness related to the consumption of Diamond Shruumz products, leading to 23 hospitalizations. Individuals reported a range of symptoms, from seizures to nausea, prompting the FDA to caution against consuming the company’s chocolates.
Despite claims from Diamond Shruumz that their products do not contain psychedelic substances like psilocybin, the FDA is urging consumers to avoid ingesting the chocolates due to the potential health risks associated with the undisclosed ingredients. The company’s website touts the products as offering a unique experience without the use of scheduled drugs.
As the FDA continues to assess the situation and evaluate the health risks posed by Diamond Shruumz products, it remains crucial for consumers to remain vigilant about the products they consume. With the recall in place and ongoing investigations, it is essential for individuals to prioritize their health and safety when choosing food products.
In response to inquiries, Diamond Shruumz has yet to provide a comment on the recall and the potential health risks associated with their products. As the situation unfolds, regulators and consumers alike are closely monitoring developments to ensure the protection of public health.